HSAI
Hesai Group
HSAI has the edge over LCID overall, supported by stronger fundamentals and stronger modeled upside.
LCID
Lucid Group, Inc.
LCID has slightly lower modeled downside risk, despite its lower overall score.
HSAI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Stable | |
| Healthy |
HSAI's revenue and balance sheet are currently healthy, and its profitability and cash flow are stable.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HSAI PE Valuation
HSAI has no meaningful PE right now: it lost money over the past year.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
HSAI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for HSAI, with profitability improving. However, they disagree widely on these estimates.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HSAI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.48 | +336% |
| Q1 2026 | $0.47 | +$0.49 |
| Q4 2025 | $0.43 | +$0.56 |
| Q3 2025 | $0.46 | +$0.92 |
| Q2 2025 | $0.11 | +$0.66 |
| Q1 2025 | -$0.02 | +$0.53 |
| Q4 2024 | -$0.13 | +$0.44 |
| Q3 2024 | -$0.46 | +$0.11 |
HSAI has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
HSAI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $129.2M | +22% |
| Q1 2026 | $102.1M | +30% |
| Q4 2025 | $150.1M | +39% |
| Q3 2025 | $119.4M | +47% |
| Q2 2025 | $106M | +54% |
| Q1 2025 | $78.8M | +46% |
| Q4 2024 | $108M | +28% |
| Q3 2024 | $81M | +21% |
HSAI's revenue has grown year over year for nine quarters in a row: $129M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 0.3% | -3 points |
| Q1 2026 | -1.3% | +5.1 points |
| Q4 2025 | 5.7% | -9.1 points |
| Q3 2025 | 9.7% | +24 points |
| Q2 2025 | 3.2% | +24 points |
| Q1 2025 | -6.4% | +32 points |
| Q4 2024 | 15% | +44 points |
| Q3 2024 | -14% | +23 points |
HSAI has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over HSAI on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
HSAI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | $0 |
| Q1 2026 | $0 | $0 |
| Q4 2025 | $0 | $0 |
| Q3 2025 | $0 | $0 |
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
HSAI's free cash flow was $0 over the past year, against $0 the year before.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has the edge over HSAI on cash flow, with more consistent year-over-year improvement.
HSAI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +17% | +24M shares |
| 3 years | +30% | +37.5M shares |
| 5 years | +69% | +66.7M shares |
| Available history | +84% | +74.6M shares |
HSAI has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
HSAI hasn't bought back shares in the past year.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
HSAI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -1.5x | Net Cash |
| Q1 2026 | -0.5x | Net Cash |
| Q4 2025 | -1.3x | Net Cash |
| Q3 2025 | -3.2x | Net Cash |
| Q2 2025 | -9.7x | Net Cash |
| Q1 2025 | -58.4x | Net Cash |
HSAI has more cash than debt.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HSAI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.4 | Neutral |
| Stochastic | 20.8 | Neutral |
HSAI's weekly RSI is 42 (neutral) and its Stochastic is 21 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
HSAI PE vs Consumer Cyclical Sector
| Metric | HSAI | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
HSAI has no meaningful PE right now: it lost money over the past year.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
HSAI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.2 | 0.4% below |
| 20 week MA | $16.0 | 12% below |
| 50 week MA | $20.0 | 29% below |
| 100 week MA | $19.8 | 28% below |
LCID has stronger trend alignment. HSAI is above 0 of 4 weekly averages versus LCID above 0 of 5.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
HSAI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $22.2 | $8.91 | -60% |
| 2024 | $8.91 | $13.5 | +52% |
| 2025 | $13.5 | $22.5 | +67% |
| 2026 YTD | $22.5 | $14.2 | -37% |
HSAI has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.